Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academic collaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders. The company intends to achieve this goal by:
  • focusing primarily on chromatin biology to build a balanced pipeline, by selecting a broad range of targets with differing mechanistic actions
  • leveraging its links with leading chromatin researchers to provide a renewable pipeline of innovative programme's and a strong intellectual property portfolio
  • focusing its strong medicinal chemistry capabilities on producing only first-in-class or best-in-class drugs
  • utilising its novel cell accumulation approach (ESM technology) to enhance its core chromatin programmes, as well as building a highly valuable portfolio of drugs for the treatment of cancer and inflammatory disorders
  • building substantial shareholder value through a balance of in-house development and selected strategic alliances which preserve significant downstream rights

Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797

Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Cell Accumulation Approach